Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study
Authors:
Open Access
- 30 August 2022
- journal article
- research article
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 20 (6) , 845-856
Abstract
Background The total economic burden of cancer reflects direct and indirect costs, including productivity loss due to employment change, absenteeism, and presenteeism of patients and caregivers. Objective This study estimated the magnitude of employment decrease, work absence (WA), short-term disability (STD), long-term disability (LTD), and associated indirect costs among employees newly diagnosed with metastatic versus non-metastatic cancer in the USA. Methods IBM® MarketScan® Commercial Claims and Encounters and Health and Productivity Management databases were used to identify employees aged 18–64 years and newly diagnosed with any cancer from 2009 to 2019. Proportions of patients with employment decrease, WA, STD, and LTD claims, and number of days missing from work were summarized by metastatic status during the first 12 months after diagnosis and the entire follow-up period. Subgroup analyses were conducted by age (< 50 years, ≥ 50 years) and cancer type (breast, lung, colon, pancreatic, and liver cancer). Results During the first year after diagnosis, compared to patients without metastases, significantly higher proportions of patients with metastases had employment decrease and STD or LTD claims (p < 0.001). The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year. Conclusion Earlier detection of cancer may reduce productivity loss of patients and indirect costs by initiating treatment before cancer progresses to late stage.Keywords
Funding Information
- GRAIL LLC, a subsidiary of Illumina, Inc.
This publication has 19 references indexed in Scilit:
- A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and CaregiversJournal of Managed Care & Specialty Pharmacy, 2017
- Employment implications of informal cancer caregivingJournal of Cancer Survivorship, 2016
- Employment outcomes among survivors of common cancers: the Symptom Outcomes and Practice Patterns (SOAPP) studyJournal of Cancer Survivorship, 2013
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future ResearchCancer Epidemiology, Biomarkers & Prevention, 2011
- Predictors of employment (empl) outcomes in outpatients (pts) with common solid tumors: A secondary analysis from E2Z02 (ECOG's SOAPP study).Journal of Clinical Oncology, 2010
- Time costs associated with informal caregiving for cancer survivorsCancer, 2009
- Quality of life among patients with primary, metastatic and recurrent cancerEuropean Journal of Cancer Care, 2009
- Estimates and Projections of Value of Life Lost From Cancer Deaths in the United StatesJNCI: Journal of the National Cancer Institute, 2008
- How to Present the Business Case for Healthcare Quality to EmployersApplied Health Economics and Health Policy, 2005
- Estimating the Cost of Cancer: Results on the Basis of Claims Data Analyses for Cancer Patients Diagnosed With Seven Types of Cancer During 1999 to 2000Journal of Clinical Oncology, 2004